Michael Bogenschutz

Director, NYU Langone Center for Psychedelic Medicine · New York Presbyterian Hospital

Credentials: · · ·

History

NYU Langone Center for Psychedelic Medicine · New York Presbyterian Hospital
Present
NYU Langone Center for Psychedelic Medicine · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present

Neural Mechanisms of Psilocybin-Assisted Treatment for Alcohol Use Disorder.
National Institute on Alcohol Abuse and Alcoholism · R01
Contact PI · $2M · New York University School of Medicine
2024–2029
Evaluation of Psilocybin as an Adjunctive Treatment for Opioid Use Disorder in Methadone-Maintained Patients Who Continue to Use Illicit Opioids
National Institute on Drug Abuse · UG3
Contact PI · $6.4M · New York University School of Medicine
2024–2027
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid with PTSD
National Institute on Alcohol Abuse and Alcoholism · P01
Project lead · $2.3M · New York University School of Medicine
2018–2025
Effects of Cannabidiol in Alcohol Use Disorder-Resubmission-1
National Institute on Alcohol Abuse and Alcoholism · R21
Contact PI · $444.9K · New York University School of Medicine
2017–2021

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
Principal investigator · Recruiting · Phase 2
NYU Langone Health
2026–2030
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
Principal investigator · Not yet recruiting · Phase 2
NYU Langone Health
2026–2027
Psilocybin for Opioid Use Disorder (OUD)
Principal investigator · Recruiting · Phase 2
NYU Langone Health
2025–2029
Effects of Cannabidiol in Alcohol Use Disorder
Principal investigator · Completed · Phase 1, Phase 2
NYU Langone Health
2019–2022